Skip to main content
SpringerLink
Log in

Predictable Biomarkers for Rapid-Acting Antidepressant Response to Ketamine

  • Chapter
  • First Online:
New Rapid-acting Antidepressants

Part of the book series: Contemporary Clinical Neuroscience ((CCNE))

Abstract

The N-methyl-D-aspartate receptor (NMDAR) antagonist (R,S)-ketamine elicits rapid-acting and sustained antidepressant actions for treatment-resistant patients with major depressive disorder (MDD) and bipolar disorder (BD) although it is known to cause transient adverse effects such as psychotomimetic and dissociative effects in humans. Identifying specific biomarkers for MDD and BD could help establish accurate diagnoses that form the basis for more appropriate treatment. In this chapter, we discuss the potential biomarkers that can predict the rapid antidepressant response to (R,S)-ketamine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Abdallah CG, Salas R, Jackowski A, Baldwin P, Sato JR, Mathew SJ (2015) Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol 29(5):591–595

    Article  CAS  PubMed  Google Scholar 

  • Abdallah CG, Sanacora G, Duman RS, Krystal JH (2018) The neurobiology of depression, ketamine and rapid-acting antidepressants: is it glutamate inhibition or activation? Pharmacol Ther 190:148–158

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, Kraus C, Kadriu B, Zarate CA, Park LT (2020) Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. J Affect Disord 263:568–575

    Article  CAS  PubMed  Google Scholar 

  • Allen AP, Naughton M, Dowling J, Walsh A, Ismail F, Shorten G, Scott L, McLoughlin DM, Cryan JF, Dinan TG, Clarke G (2015) Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT. J Affect Disord 186:306–311

    Article  CAS  PubMed  Google Scholar 

  • Ballard ED, Zarate CA Jr (2020) The role of dissociation in ketamine's antidepressant effects. Nat Commun 11(1):6431

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998) Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J Trauma Stress 11(1):125–136

    Article  CAS  PubMed  Google Scholar 

  • Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, Pinter C, Hough D, Sanacora G, Manji H, Drevets WC (2018) Efficacy and safety of intranasal Esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 175(7):620–630

    Article  PubMed  Google Scholar 

  • Chen MH, Li CT, Lin WC, Hong CJ, Tu PC, Bai YM, Cheng CM, Su TP (2018) Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: a randomized, double-blind control study. Psychiatry Res 269:207–211

    Article  CAS  PubMed  Google Scholar 

  • Chen MH, Kao CF, Tsai SJ, Li CT, Lin WC, Hong CJ, Bai YM, Tu PC, Su TP (2021a) Treatment response to low-dose ketamine infusion for treatment-resistant depression: a gene-based genome-wide association study. Genomics 113(2):507–514

    Google Scholar 

  • Chen X, Wang M, Hu Y, Zhan Y, Zhou Y, Zheng W, Liu W, Wang C, Zhong X, Li H, Lan X, Ning Y, Zhang B (2021b) Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients. Advance online publication. Eur Arch Psychiatry Clin Neurosci. https://doi.org/10.1007/s00406-020-01221-z

  • Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, Grillon C, Zarate CA Jr (2012) Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry 72(7):555–561

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Crisanti C, Enrico P, Fiorentini A, Delvecchio G, Brambilla P (2020) Neurocognitive impact of ketamine treatment in major depressive disorder: a review on human and animal studies. J Affect Disord 276:1109–1118

    Article  CAS  PubMed  Google Scholar 

  • Dale RM, Bryant KA, Thompson NR (2020) Metabolic syndrome rather than body mass index is associated with treatment response to ketamine infusions. J Clin Psychopharmacol 40(1):75–79

    Article  PubMed  Google Scholar 

  • Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC (2018) Efficacy and safety of intranasal Esketamine adjunctive to Oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiat 75(2):139–148

    Article  Google Scholar 

  • DALYs and HALE Collaborators, Murray CJ, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, Abd-Allah F, Abera SF, Aboyans V, Abraham JP, Abubakar I, Abu-Raddad LJ, Abu-Rmeileh NM, Achoki T, Ackerman IN, Ademi Z, Adou AK, Adsuar JC, Afshin A, Agardh EE, Alam SS et al (2015) Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 386(10009):2145–2191

    Article  Google Scholar 

  • Duncan WC Jr, Slonena E, Hejazi NS, Brutsche N, Yu KC, Park L, Ballard ED, Zarate CA Jr (2017) Motor-activity markers of circadian timekeeping are related to Ketamine's rapid antidepressant properties. Biol Psychiatry 82(5):361–369

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Duncan WC Jr, Slonena EE, Hejazi NS, Brutsche N, Park LT, Henter ID, Ballard ED, Zarate CA Jr (2018) Are 24-hour motor activity patterns associated with continued rapid response to ketamine? Neuropsychiatr Dis Treat 14:2739–2748

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Duncan WC Jr, Zarate CA Jr (2013) Ketamine, sleep, and depression: current status and new questions. Curr Psychiatry Rep 15(9):394

    Article  PubMed  Google Scholar 

  • Duncan WC, Sarasso S, Ferrarelli F, Selter J, Riedner BA, Hejazi NS, Yuan P, Brutsche N, Manji HK, Tononi G, Zarate CA (2013) Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 16(2):301–311

    Article  CAS  PubMed  Google Scholar 

  • Freeman MP, Hock RS, Papakostas GI, Judge H, Cusin C, Mathew SJ, Sanacora G, Iosifescu DV, DeBattista C, Trivedi MH, Fava M (2020) Body mass index as a moderator of treatment response to ketamine for major depressive disorder. J Clin Psychopharmacol 40(3):287–292

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Friedrich MJ (2017) Depression is the leading cause of disability around the world. JAMA 317(15):1517

    PubMed  Google Scholar 

  • Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi JI, Hashimoto K, Chaki S (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther 361(1):9–16

    Article  CAS  PubMed  Google Scholar 

  • Gandal MJ, Sisti J, Klook K, Ortinski PI, Leitman V, Liang Y, Thieu T, Anderson R, Pierce RC, Jonak G, Gur RE, Carlson G, Siegel SJ (2012) GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Transl Psychiatry 2(7):e142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gärtner M, Aust S, Bajbouj M, Fan Y, Wingenfeld K, Otte C, Heuser-Collier I, Böker H, Hättenschwiler J, Seifritz E, Grimm S, Scheidegger M (2019) Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine. Eur Neuropsychopharmacol 29(4):501–508

    Article  PubMed  CAS  Google Scholar 

  • Gilbert JR, Zarate CA Jr (2020) Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: gamma power and long-term potentiation. Pharmacol Biochem Behav 189:172856

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gill H, Gill B, Rodrigues NB, Lipsitz O, Rosenblat JD, El-Halabi S, Nasri F, Mansur RB, Lee Y, McIntyre RS (2020) The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research. Neurosci Biobehav Rev 120:78–85

    Article  PubMed  CAS  Google Scholar 

  • Godin O, Bennabi D, Yrondi A, Richieri R, D'Amato T, Bellivier F, Bougerol T, Horn M, Camus V, Courtet P, Doumy O, Genty JB, El-Hage W, Haesebaert F, Holtzmann J, Lancon C, Leboyer M, Llorca PM, Maruani J, Molière F, FondaMental Advanced Centers of Expertise in Resistant Depression (FACE-DR) Collaborators (2019) Prevalence of metabolic syndrome and associated factors in a cohort of individuals with treatment-resistant depression: results from the FACE-DR study. J Clin Psychiatry 80(6):19m12755

    Article  PubMed  Google Scholar 

  • Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC (2015) The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 76(2):155–162

    Article  PubMed  Google Scholar 

  • Gururajan A, Naughton ME, Scott KA, O'Connor RM, Moloney G, Clarke G, Dowling J, Walsh A, Ismail F, Shorten G, Scott L, McLoughlin DM, Cryan JF, Dinan TG (2016) MicroRNAs as biomarkers for major depression: a role for let-7b and let-7c. Transl Psychiatry 6(8):e862

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Haroon E, Miller AH (2017) Inflammation effects on brain glutamate in depression: mechanistic considerations and treatment implications. Curr Top Behav Neurosci 31:173–198

    Article  PubMed  CAS  Google Scholar 

  • Hashimoto K (2010) Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 64(4):341–357

    Article  CAS  PubMed  Google Scholar 

  • Hashimoto K (2014) Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine. psychopharmacology (Berl) 231(20):4081–2

    Google Scholar 

  • Hashimoto K (2015a) Brain-derived neurotrophic factor (BDNF) and its precursor proBDNF as diagnostic biomarkers for major depressive disorder and bipolar disorder. Eur Arch Psychiatry Clin Neurosci 265(1):83–84

    Article  PubMed  Google Scholar 

  • Hashimoto K (2015b) Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci 16(4):7796–7801

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hashimoto K (2016) Letter to the editor: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol Med 46(11):2449–2451

    Article  CAS  PubMed  Google Scholar 

  • Hashimoto K (2019) Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci 73(10):613–627

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hashimoto K (2020) Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol 177:113935

    Article  CAS  PubMed  Google Scholar 

  • Hashimoto K (2021) Neural rhythm in the retrosplenial cortex during ketamine-induced dissociation. Eur Arch Psychiatry Clin Neurosci 271(3):583–585

    Google Scholar 

  • Hashimoto K, Shimizu E, Iyo M (2004) Critical role of brain-derived neurotrophic factor in mood disorders. Brain research. Brain Res Rev 45(2):104–114

    Article  CAS  PubMed  Google Scholar 

  • Hashimoto K, Yang C (2019) Is (S)-norketamine an alternative antidepressant for esketamine? Eur Arch Psychiatry Clin Neurosci 269(7):867–868

    Article  PubMed  Google Scholar 

  • Hashimoto K, Yoshida T, Ishikawa M, Fujita Y, Niitsu T, Nakazato M, Watanabe H, Sasaki T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura A, Iyo M (2016) Increased serum levels of serine enantiomers in patients with depression. Acta Neuropsychiatrica 28(3):173–178

    Article  PubMed  Google Scholar 

  • Hasler BP, Buysse DJ, Kupfer DJ, Germain A (2010) Phase relationships between core body temperature, melatonin, and sleep are associated with depression severity: further evidence for circadian misalignment in non-seasonal depression. Psychiatry Res 178(1):205–207

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Herrera-Melendez A, Stippl A, Aust S, Scheidegger M, Seifritz E, Heuser-Collier I, Otte C, Bajbouj M, Grimm S, Gärtner M (2021) Gray matter volume of rostral anterior cingulate cortex predicts rapid antidepressant response to ketamine. Eur Neuropsychopharmacol 43:63–70

    Google Scholar 

  • Huber R, Tononi G, Cirelli C (2007) Exploratory behavior, cortical BDNF expression, and sleep homeostasis. Sleep 30(2):129–139

    Article  PubMed  Google Scholar 

  • Ionescu DF, Felicione JM, Gosai A, Cusin C, Shin P, Shapero BG, Deckersbach T (2018) Ketamine-associated brain changes: a review of the neuroimaging literature. Harv Rev Psychiatry 26(6):320–339

    Article  PubMed  PubMed Central  Google Scholar 

  • Kadriu B, Ballard ED, Henter ID, Murata S, Gerlus N, Zarate CA Jr (2020) Neurobiological biomarkers of response to ketamine. Adv Pharmacol 89:195–235

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kadriu B, Gold PW, Luckenbaugh DA, Lener MS, Ballard ED, Niciu MJ, Henter ID, Park LT, De Sousa RT, Yuan P, Machado-Vieira R, Zarate CA (2018) Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. Mol Psychiatry 23(7):1626–1631

    Article  CAS  PubMed  Google Scholar 

  • Kiraly DD, Horn SR, Van Dam NT, Costi S, Schwartz J, Kim-Schulze S, Patel M, Hodes GE, Russo SJ, Merad M, Iosifescu DV, Charney DS, Murrough JW (2017) Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry 7(3):e1065

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS (2019) Ketamine: a paradigm shift for depression research and treatment. Neuron 101(5):774–778

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3):199–214

    Article  CAS  PubMed  Google Scholar 

  • Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C Jr (2012) Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry 72(11):e27–e28

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa L, Marback RF, Caliman-Fontes AT, Marques B, Bezerra M, Dias-Neto AL, Silva SS, Sampaio AS, Sanacora G, Turecki G, Loo C, Lacerda A, Quarantini LC (2021) Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci 271(3):577–582

    Google Scholar 

  • Liu W, Zhou Y, Zheng W, Wang C, Zhan Y, Lan X, Zhang B, Li H, Chen L, Ning Y (2019) Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression. J Affect Disord 259:1–6

    Article  CAS  PubMed  Google Scholar 

  • Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche NE, Guevara S, Zarate CA (2014) Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord 159:56–61

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lundin NB, Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Brutsche NE, Machado-Vieira R, Zarate CA Jr (2014) Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine. Pharmacopsychiatry 47(4–5):141–144

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lv Q, Yang L, Li G, Wang Z, Shen Z, Yu W, Jiang Q, Hou B, Pu J, Hu H, Wang Z (2016) Large-scale persistent network reconfiguration induced by ketamine in anesthetized monkeys: relevance to mood disorders. Biol Psychiatry 79(9):765–775

    Article  CAS  PubMed  Google Scholar 

  • Mastrodonato A, Cohensedgh O, LaGamma CT, McGowan JC, Hunsberger HC, Denny CA (2020) Prophylactic (R,S)-ketamine selectively protects against inflammatory stressors. Behav Brain Res 378:112238

    Article  CAS  PubMed  Google Scholar 

  • Mathai DS, Meyer MJ, Storch EA, Kosten TR (2020) The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: a systematic review. J Affect Disord 264:123–129

    Article  PubMed  Google Scholar 

  • McIntyre RS, Lee Y (2016) Cognition in major depressive disorder: a 'Systemically important functional Index' (SIFI). Curr Opin Psychiatry 29(1):48–55

    Article  PubMed  Google Scholar 

  • McMillan R, Sumner R, Forsyth A, Campbell D, Malpas G, Maxwell E, Deng C, Hay J, Ponton R, Sundram F, Muthukumaraswamy S (2020) Simultaneous EEG/fMRI recorded during ketamine infusion in patients with major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 99:109838

    Article  CAS  Google Scholar 

  • Metzner J, Domino KB (2010) Risks of anesthesia or sedation outside the operating room: the role of the anesthesia care provider. Curr Opin Anaesthesiol 23(4):523–531

    Article  PubMed  Google Scholar 

  • Mkrtchian A, Evans JW, Kraus C, Yuan P, Kadriu B, Nugent AC, Roiser JP, Zarate CA Jr (2020) Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. Molecular Psychiatry, Advance online publication. https://doi.org/10.1038/s41380-020-00878-1

  • Moaddel R, Luckenbaugh DA, Xie Y, Villaseñor A, Brutsche NE, Machado-Vieira R, Ramamoorthy A, Lorenzo MP, Garcia A, Bernier M, Torjman MC, Barbas C, Zarate CA Jr, Wainer IW (2015) D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology 232(2):399–409

    Article  CAS  PubMed  Google Scholar 

  • Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, Foulkes A, Charney DS, Mathew SJ, Iosifescu DV (2015) Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology 40(5):1084–1090

    Article  CAS  PubMed  Google Scholar 

  • Niciu MJ, Iadarola ND, Banerjee D, Luckenbaugh DA, Park M, Lener M, Park L, Ionescu DF, Ballard ED, Brutsche NE, Akula N, McMahon FJ, Machado-Vieira R, Nugent AC, Zarate CA Jr (2017) The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. J Psychopharmacol 31(12):1570–1577

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Niciu MJ, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM, Brutsche NE, Nolan NM, Zarate CA Jr (2014) Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry 75(5):e417–e423

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nugent AC, Ballard ED, Gilbert JR, Tewarie PK, Brookes MJ, Zarate CA Jr (2020) The effect of ketamine on electrophysiological connectivity in major depressive disorder. Front Psych 11:519

    Article  Google Scholar 

  • Nugent AC, Ballard ED, Gould TD, Park LT, Moaddel R, Brutsche NE, Zarate CA Jr (2019a) Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol Psychiatry 24(7):1040–1052

    Article  CAS  PubMed  Google Scholar 

  • Nugent AC, Wills KE, Gilbert JR, Zarate CA Jr (2019b) Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: a replication study. Psychiatry Res Neuroimaging 283:64–66

    Article  PubMed  Google Scholar 

  • Ortiz R, Niciu MJ, Lukkahati N, Saligan LN, Nugent AC, Luckenbaugh DA, Machado-Vieira R, Zarate CA Jr (2015) Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. J Affect Disord 172:307–311

    Article  CAS  PubMed  Google Scholar 

  • Park M, Newman LE, Gold PW, Luckenbaugh DA, Yuan P, Machado-Vieira R, Zarate CA Jr (2017) Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression. J Psychiatr Res 84:113–118

    Article  PubMed  Google Scholar 

  • Permoda-Osip A, Dorszewska J, Bartkowska-Sniatkowska A, Chlopocka-Wozniak M, Rybakowski JK (2013) Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression. Pharmacopsychiatry 46(6):227–228

    Article  CAS  PubMed  Google Scholar 

  • Phillips ML, Chase HW, Sheline YI, Etkin A, Almeida JR, Deckersbach T, Trivedi MH (2015) Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. Am J Psychiatry 172(2):124–138

    Article  PubMed  PubMed Central  Google Scholar 

  • Price JL, Drevets WC (2012) Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci 16(1):61–71

    Article  PubMed  Google Scholar 

  • Rivas-Grajales AM, Salas R, Robinson ME, Qi K, Murrough JW, Mathew SJ (2021) Habenula connectivity and intravenous ketamine in treatment-resistant depression. Inter J Neuropsychopharmacol 24(5):383–391

    Google Scholar 

  • Rong C, Park C, Rosenblat JD, Subramaniapillai M, Zuckerman H, Fus D, Lee YL, Pan Z, Brietzke E, Mansur RB, Cha DS, Lui L, McIntyre RS (2018) Predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder. Int J Environ Res Public Health 15(4):771

    Article  PubMed Central  CAS  Google Scholar 

  • Sahib AK, Loureiro JR, Vasavada M, Anderson C, Kubicki A, Wade B, Joshi SH, Woods RP, Congdon E, Espinoza R, Narr KL (2020a) Modulation of the functional connectome in major depressive disorder by ketamine therapy. Psycholog Med Advance online publication:1–10. https://doi.org/10.1017/S0033291720004560

  • Sahib AK, Loureiro JR, Vasavada MM, Kubicki A, Wade B, Joshi SH, Woods RP, Congdon E, Espinoza R, Narr KL (2020b) Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression. Transl Psychiatry 10(1):260

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA Jr, Manji HK (2009) Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 65(4):289–295

    Article  CAS  PubMed  Google Scholar 

  • Schoeman JC, Steyn SF, Harvey BH, Brink CB (2017) Long-lasting effects of fluoxetine and/or exercise augmentation on bio-behavioural markers of depression in pre-pubertal stress sensitive rats. Behav Brain Res 323:86–99

    Article  CAS  PubMed  Google Scholar 

  • Shimizu E, Hashimoto K, Iyo M (2004) Ethnic difference of the BDNF 196G/a (val66met) polymorphism frequencies: the possibility to explain ethnic mental traits. American journal of medical genetics. Part B. Neuropsychiatric Genetics 126B(1):122–123

    Article  PubMed  Google Scholar 

  • Shiroma PR, Thuras P, Wels J, Albott CS, Erbes C, Tye S, Lim KO (2020) Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 277:470–477

    Article  CAS  PubMed  Google Scholar 

  • Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC, Van Nueten L (2016) Intravenous Esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80(6):424–431

    Article  CAS  PubMed  Google Scholar 

  • Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, Tu PC, Bai YM, Cheng CM, Krystal JH (2017) Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology 42(13):2482–2492

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tan Y, Fujita Y, Qu Y, Chang L, Pu Y, Wang S, Wang X, Hashimoto K (2020) Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: role of BDNF-TrkB signaling. Pharmacol Biochem Behav 188:172839

    Article  CAS  PubMed  Google Scholar 

  • Thomas SJ, Shin M, McInnis MG, Bostwick JR (2015) Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. Pharmacotherapy 35(4):433–449

    Article  CAS  PubMed  Google Scholar 

  • Vande Voort JL, Ballard ED, Luckenbaugh DA, Bernert RA, Richards EM, Niciu MJ, Park LT, Machado-Vieira R, Duncan WC Jr, Zarate CA Jr (2017) Antisuicidal response following ketamine infusion is associated with decreased nighttime wakefulness in major depressive disorder and bipolar disorder. J Clin Psychiatry 78(8):1068–1074

    Article  PubMed  PubMed Central  Google Scholar 

  • Vasavada MM, Leaver AM, Espinoza RT, Joshi SH, Njau SN, Woods RP, Narr KL (2016) Structural connectivity and response to ketamine therapy in major depression: a preliminary study. J Affect Disord 190:836–841

    Article  CAS  PubMed  Google Scholar 

  • Vesuna S, Kauvar IV, Richman E, Gore F, Oskotsky T, Sava-Segal C, Luo L, Malenka RC, Henderson JM, Nuyujukian P, Parvizi J, Deisseroth K (2020) Deep posteromedial cortical rhythm in dissociation. Nature 586(7827):87–94

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J (1997) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 7(1):25–38

    Article  CAS  Google Scholar 

  • Wang M, Zhang B, Zhou Y, Wang C, Zheng W, Liu W, Zhan Y, Lan X, Ning Y (2021) Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis. Pharmacological Reports, PR Advance online publication. https://doi.org/10.1007/s43440-020-00203-1

  • Wei Y, Chang L, Hashimoto K (2020) A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacol Biochem Behav 190:172870

    Article  CAS  PubMed  Google Scholar 

  • Wei Y, Chang L, Hashimoto K (2021) Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Mol Psychiatry 2021 May 7. https://doi.org/10.1038/s41380-021-01121-1. 

  • Xie ZM, Wang XM, Xu N, Wang J, Pan W, Tang XH, Zhou ZQ, Hashimoto K, Yang JJ (2017) Alterations in the inflammatory cytokines and brain-derived neurotrophic factor contribute to depression-like phenotype after spared nerve injury: improvement by ketamine. Sci Rep 7(1):3124

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Xiong Z, Fujita Y, Zhang K, Pu Y, Chang L, Ma M, Chen J, Hashimoto K (2019) Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model. Behav Brain Res 368:111904

    Article  CAS  PubMed  Google Scholar 

  • Yang C, Kobayashi S, Nakao K, Dong C, Han M, Qu Y, Ren Q, Zhang JC, Ma M, Toki H, Yamaguchi JI, Chaki S, Shirayama Y, Nakazawa K, Manabe T, Hashimoto K (2018a) AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-Norketamine. Biol Psychiatry 84(8):591–600

    Article  CAS  PubMed  Google Scholar 

  • Yang C, Ren Q, Qu Y, Zhang JC, Ma M, Dong C, Hashimoto K (2018b) Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry 83(1):18–28

    Article  CAS  PubMed  Google Scholar 

  • Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015a) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5(9):e632

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yang C, Wardenaar KJ, Bosker FJ, Li J, Schoevers RA (2019a) Inflammatory markers and treatment outcome in treatment resistant depression: a systematic review. J Affect Disord 257:640–649

    Article  CAS  PubMed  Google Scholar 

  • Yang C, Yang J, Luo A, Hashimoto K (2019b) Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl Psychiatry 9(1):280

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Yang JJ, Wang N, Yang C, Shi JY, Yu HY, Hashimoto K (2015b) Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry 77(3):e19–e20

    Article  CAS  PubMed  Google Scholar 

  • Zhan Y, Zhou Y, Zheng W, Liu W, Wang C, Lan X, Deng X, Xu Y, Zhang B, Ning Y (2020) Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder. Transl Psychiatry 10(1):246

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang JC, Li SX, Hashimoto K (2014) R(−)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav 116:137–141

    Article  CAS  PubMed  Google Scholar 

  • Zhang JC, Yao W, Hashimoto K (2016) Brain-derived neurotrophic factor (BDNF)-TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr Neuropharmacol 14(7):721–731

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang K, Hashimoto K (2019) An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother 19(1):83–92

    Article  CAS  PubMed  Google Scholar 

  • Zhang K, Ma M, Dong C, Hashimoto K (2018) Role of inflammatory bone markers in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model. Int J Neuropsychopharmacol 21(11):1025–1030

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang K, Yang C, Chang L, Sakamoto A, Suzuki T, Fujita Y, Qu Y, Wang S, Pu Y, Tan Y, Wang X, Ishima T, Shirayama Y, Hatano M, Tanaka KF, Hashimoto K (2020) Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1. Transl Psychiatry 10(1):32

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zheng W, Zhou YL, Wang CY, Lan XF, Zhang B, Yang MZ, Nie S, Ning YP (2020) Neurocognitive effects of six ketamine infusions and the association with antidepressant effects in treatment-resistant bipolar depression: a preliminary study. PeerJ 8:e10208

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zhong M, Wang X, Xiao J, Yi J, Zhu X, Liao J, Wang W, Yao S (2011) Amygdala hyperactivation and prefrontal hypoactivation in subjects with cognitive vulnerability to depression. Biol Psychol 88(2–3):233–242

    Article  PubMed  Google Scholar 

  • Zhou Y, Zheng W, Liu W, Wang C, Zhan Y, Li H, Chen L, Li M, Ning Y (2018a) Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. Brain Behav Immun 74:205–212

    Article  CAS  PubMed  Google Scholar 

  • Zhou Y, Zheng W, Liu W, Wang C, Zhan Y, Li H, Chen L, Li M, Ning Y (2018b) Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. J Psychopharmacol 32(10):1118–1126

    Article  CAS  PubMed  Google Scholar 

  • Zhou YL, Wu FC, Liu WJ, Zheng W, Wang CY, Zhan YN, Lan XF, Ning YP (2020a) Volumetric changes in subcortical structures following repeated ketamine treatment in patients with major depressive disorder: a longitudinal analysis. Transl Psychiatry 10(1):264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhou YL, Wu FC, Wang CY, Zheng W, Lan XF, Deng XR, Ning YP (2020b) Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder. J Affect Disord 276:608–615

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by AMED (to K.H., JP20dm0107119).

Conflict of Interest

Dr. Hashimoto is the inventor of filed patent applications on “The use of R-ketamine in the treatment of psychiatric diseases,” “(S)-norketamine and salt thereof as pharmaceutical,” “R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder,” “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases,” and “R-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. Dr. Hashimoto has received the research support from Dainippon Sumitomo, Otsuka, and Taisho. Dr. Tan declares no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan

    Yunfei Tan & Kenji Hashimoto

  2. Department of Psychiatry, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

    Yunfei Tan

Authors
  1. Yunfei Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenji Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenji Hashimoto .

Editor information

Editors and Affiliations

  1. Center for Forensic Mental Health, Chiba University, Chiba, Japan

    Kenji Hashimoto

  2. Service de Neurologie, CHU-Charleroi, Bruxelles, Belgium

    Mario Manto

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tan, Y., Hashimoto, K. (2021). Predictable Biomarkers for Rapid-Acting Antidepressant Response to Ketamine. In: Hashimoto, K., Manto, M. (eds) New Rapid-acting Antidepressants. Contemporary Clinical Neuroscience. Springer, Cham. https://doi.org/10.1007/978-3-030-79790-4_3

Download citation

Publish with us

Policies and ethics

Search

Navigation